Agency IQ

MARCH 7, 2024

BY WALKER LIVINGSTON, ESQ The FDA has announced an update to its List of Select Chemicals in the Food Supply Under FDA Review, which details the agency’s ongoing post-market assessments for chemicals in human food. Fill out the form to read the full article. This marks the first update to the list, which first debuted in July 2023.

FDA 59

FDA Packaging Marketing 59

Agency IQ

JUNE 9, 2023

What will the orphan drug market exclusivity haircut mean for industry? Here, we’re starting some deeper analysis of aspects of the proposal package with a look at the impact of orphan drug provisions, seeing what impact the new provisions and the surrounding uncertainty might have on innovation. Orphan designation in the E.U.

Marketing 40

Marketing Regulations Biosimilars Drugs 40

Agency IQ

AUGUST 4, 2023

This past week, the MHRA provided guidance on labeling of medicines destined for Northern Ireland, with provisions to ensure that medicines only move into Northern Ireland market and don’t re-enter E.U. The European centralized marketing authorization procedure is no longer a valid medicines approval pathway for the U.K. member states.

Packaging 40

Packaging Licensing Licensing Regulations 40

Agency IQ

AUGUST 23, 2024

BY Scott Stephens, MPA | Aug 19, 2024 9:33 PM CDT Background: classifying chemicals in the EU The EU uses the United Nations (UN) Globally Harmonized System (GHS) as the basis for classifying, labeling and packaging hazardous substances and mixtures. Currently, the CLP is aligned with the seventh revised edition of the GHS.

Packaging 40

Packaging Regulations Compliance Production 40

BioPharma Drive: Drug Pricing

JUNE 23, 2025

The black and gray market risks Ben warned about the proliferation of counterfeit GLP-1 drugs in unregulated markets, posing significant dangers to patients who might unknowingly use ineffective or harmful products. You can unsubscribe at anytime. The balance is complex, as obesity carries its own serious health risks.

Treatment 130

Treatment Drugs Therapies FDA 130

Agency IQ

JUNE 7, 2024

The PPPR framework governs the authorization, sale, and use of PPPs, establishing a pre-market approval process for active substances – the pesticide components which control pests, weeds, and plant diseases – and for synergists and safeners before they can be allowed for use in PPPs.

Regulations 40

Regulations Animal Testing Production Marketing 40

Agency IQ

SEPTEMBER 29, 2023

On October 5, the European Parliament (EP) plenary is scheduled to debate and likely vote on its position on the proposed regulation for reforming Regulation (EC) No 1272/2008 on classification, labeling and packaging of substances and mixtures (CLP). food packaging, kitchen and tableware and food processing equipment).

Regulations 40

Regulations Packaging Production Marketing 40

Agency IQ

APRIL 12, 2024

Additionally, reform package included revisions of the regulations for pediatric medicines and orphan drugs. Heated debates on the most contentious issues resulted in a compromise text for each legislation in March The proposal package , consisting of one directive and one regulation, was finally released in April 2023. citizens; 2.

Pharmaceuticals 40

Pharmaceuticals Regulations Packaging Marketing 40

Agency IQ

SEPTEMBER 22, 2023

It appears the issue is largely the result of unclear labeling for biocidal disinfectants, an aspect French regulators may flag in future market authorization evaluations for these products. Article 69 of the BPR regulates the labeling of all biocides, including biocidal disinfectants.

Regulations 40

Regulations Production Packaging Marketing 40

Agency IQ

NOVEMBER 3, 2023

Jan Schakwosky has introduced the No Toxics in Food Packaging Act of 2023, which seeks to ban the use of ortho-phthalates, per- and polyfluoroalkyl substances, bisphenol compounds, styrene, and antimony trioxide as food contact substances. No Toxics in Food Packaging Act of 2023 On October 26, 2023, Reps. Key Documents and Dates H.R.

Packaging 40

Packaging FDA Regulations Production 40

The Premier Consulting Blog

MAY 4, 2023

The global ophthalmic drugs market size was valued at $33.81 The new guidance provides detailed information to applicants and manufacturers regarding compliance with the requirements in 21 CFR Part 4 for ophthalmic drugs packaged with eye cups, eye droppers, or other dispensers. 2] On April 16, 2021, the U.S.

FDA 52

FDA Packaging Regulations Compliance 52

Agency IQ

JUNE 17, 2024

This obligation to adhere to “self-regulation” (“Selbstkontrolle” in German) is laid out in Article 5 of ChemG and Article 26 of USG. see the explanatory document regarding Annex 3 in French) [ For more background, see AgencyIQ’s January 24 article. the authorization list).

Regulations 40

Regulations Production International Packaging 40

Agency IQ

FEBRUARY 12, 2024

FDA and EMA re-launch parallel advice pilot for complex generics The path to market for complex generics and hybrid products is complicated, and regulatory harmonization efforts in this space are lacking. Getting a complex generic or hybrid medicine to market is challenging. Both agencies must grant the meeting request to move forward.

FDA 40

FDA Packaging Production International 40

Agency IQ

OCTOBER 27, 2023

aligns the rules with other EU chemicals legislation – notably on biocidal products and classification, labeling and packaging. It amends the limit value for the presence of HBCDD as an unintentional trace contaminant in substances, mixtures and articles. food packaging, kitchen and tableware and food processing equipment).

Regulations 40

Regulations Production Packaging Marketing 40

Agency IQ

JUNE 28, 2024

New guidance provides definition for orphan device, offers alternative trial designs New guidance from the European Commission outlines alternatives for full pre-market clinical trials for orphan devices, defined by the Commission for the first time. Sections 5 – 9 are labeled as Part A and cover clinical evaluation considerations.

Trials 40

Trials Marketing Clinical Trials Disease 40

Agency IQ

MAY 3, 2024

It amends the limit value for the presence of PBDEs in mixtures or articles. Proposal for Regulation Initiative entry Preventing terrorism – new rules on the marketing and use of high-risk chemicals Adoption was planned for Q3 2023 This initiative establishes rules on the marketing and use of high-risk chemicals.

Regulations 40

Regulations Packaging Production International 40

Agency IQ

NOVEMBER 27, 2023

The FDA estimated that the products containing the affected API had likely been on the market for about four years before this discovery. According to the last update, MHRA plans to align with international guidelines as far as possible, while communicating directly with marketing authorization holders about any diverging assessments.

Regulations 40

Regulations Production FDA Marketing 40

Agency IQ

JULY 26, 2024

Prior to CARES Act reforms, FDA relied on a monograph process through which firms could bring OTC drugs to market without FDA approval so long as they adhered to pre-set terms under the monograph. Read AgencyIQ’s explainer on the CARES Act here. What should be submitted to which portal?

FDA 40

FDA Production Regulations Packaging 40

Agency IQ

FEBRUARY 2, 2024

Proposal for Delegated Regulation Initiative entry Draft act Persistent organic pollutants – hexabromocyclododecane (HBCDD) Adoption was planned for first quarter of 2022 This act amends the limit value for the presence of HBCDD as an unintentional trace contaminant in substances, mixtures and articles.

Regulations 40

Regulations Production Government Marketing 40

Agency IQ

DECEMBER 1, 2023

For more background on the glyphosate authorization, see AgencyIQ’s October 12 article.] This measure will reduce the maximum PFOS concentration allowed as unintentional trace contaminant in substances, mixtures and articles and will remove the last specific exemption allowed in the EU since it is no longer needed.

Regulations 40

Regulations Production International Marketing 40

Agency IQ

MARCH 1, 2024

ECHA consultations under BPR closing in March BPR: Potential candidates for substitution These consultations support the evaluating competent authority in assessing the availability of substitutes or alternatives to active substances found to be potential candidates for substitution in accordance with Article 10 of the BPR.

Regulations 40

Regulations Production Packaging Science 40

Agency IQ

JANUARY 4, 2024

The Commission may be close to delivering this proposal , given that the EU executive recently adopted a package of related draft legislation in support of the CSS’s one substance-one assessment (1S1A) ambition. Two of the package’s proposed acts address the reattribution of tasks among EU agencies associated with chemical safety assessments.

Regulations 40

Regulations Packaging Production Government 40

Agency IQ

JUNE 7, 2024

The regulations increase focus on post-market requirements and expect continuous and instantaneous updates to all reports and documents when either the product or the benefit-risk ratio changes. The earliest a Notified Body could be designated to the MDR and IVDR was November 2017, according to MDR Article 123 and IVDR Article 113.

Regulations 40

Regulations Compliance Packaging Production 40

Agency IQ

JANUARY 26, 2024

FDA proposes first update to orthopedic device coating guidance since 1990s The FDA’s Center for Devices and Radiological Health (CDRH) has issued a new draft guidance specifically laying out the types of information it would want to see in pre-market submission for orthopedic devices with specific coating types.

FDA 40

FDA Animal Testing Packaging Regulations 40

Agency IQ

MAY 31, 2024

It amends the limit value for the presence of PBDEs in mixtures or articles. Proposal for Regulation Initiative entry Preventing terrorism – new rules on the marketing and use of high-risk chemicals Adoption was planned for Q3 2023 This initiative establishes rules on the marketing and use of high-risk chemicals.

Regulations 40

Regulations Production International Government 40

The Premier Consulting Blog

MAY 11, 2023

The guidance provides information to biopharma manufacturers regarding ophthalmic drugs packaged with eye cups, eye droppers, or other ophthalmic dispensers, where those articles meet the device definition. Case 3: Pre-Approval Product 1 The marketing application for Product 1 was submitted before issuance of the new guidance.

FDA 52

FDA Compliance Regulations Production 52

Agency IQ

MARCH 7, 2024

The “Collaboration” session, the subject of this article, encompassed three smaller segments – two shorter one-on-one interviews, and a one-hour panel discussion with representatives from EU government, trade associations, and the non-profit sector. see AgencyIQ’s article here for background on 1S1A.] “If

Regulations 40

Regulations International Government Compliance 40

Agency IQ

JUNE 26, 2023

incentives for rare disease-focused drug development were first enacted in 1983 under the Orphan Drug Act, including market exclusivities (7 years of marketing exclusivity), waivers from certain user fees, and tax credits for certain development activities (currently worth 25% of development costs). In the U.S.,

FDA 40

FDA Disease Regulations Production 40

Drug Target Review

JULY 18, 2023

This article is the second part of my interview with Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, this time exploring the AI applications in personalised medicine, and the evolving landscape of drug development.

Drug Development 98

Drug Development Drugs Clinical Development Pharmaceutical Companies 98

Agency IQ

MAY 3, 2024

The pharma reform package remains in E.U. In the interim, the European Council will continue to discuss the package, and stakeholders may gain some insight into the Council’s thinking near the end of May. leaders’ eyesight as the Parliament winds down ahead of its June elections. On April 10, the E.U. On April 10, the E.U.

Regulations 40

Regulations Clinical Trials Production Biosimilars 40

Agency IQ

JANUARY 12, 2024

The Prescription Drug User Fee Act (PDUFA) authorizes the FDA to collect fees from companies that submit marketing applications to the agency for certain human drug and biological products. Fees are also used for a host of other activities meant to improve the FDA’s regulatory capacity and capabilities, such as I.T. modernization efforts.

FDA 40

FDA Drugs Production Licensing 40

Agency IQ

APRIL 12, 2024

Referencing the condition for phase 2 or 3 studies, PhRMA asked that the agency modify its language to clarify that such a hold would only apply in situations when the study is intended “to provide substantial evidence of effectiveness for a marketing application.” Should potency assurance plans be submitted? If so, how?

Production 40

Production FDA Therapies Biochemical Assays 40

Perficient: Drug Development

SEPTEMBER 11, 2023

If you read my last article, the big deal with headless , you know that the big deal is performance. Experience Edge accelerates content delivery but does not support Sitecore Analytics or Marketing features. It includes Experience Edge as part of the package, offering the same benefits mentioned in Option 2.

Licensing 52

Licensing Licensing Packaging Marketing 52

Agency IQ

OCTOBER 6, 2023

For an in-depth analysis of this restriction proposal, read AgencyIQ’s February 10, 2023 article here.] The specifics of the analysis campaigns facility operators must conduct are spelled out in article 3 of the ministerial order. A list of eight substances of particular note and which match these criteria is included in article 3.

Pharmaceuticals 40

Pharmaceuticals Regulations Production Pharmaceutical Companies 40

Agency IQ

AUGUST 2, 2024

The consultations also seek additional information from third parties to determine if relevant substances subject to Article 5(1) exclusion criteria may qualify for exemptions under Article 5(2) of BPR. It amends the limit value for the presence of PBDEs in mixtures or articles.

Regulations 40

Regulations Production Packaging International 40

Drug Target Review

DECEMBER 5, 2024

2 However, utilisation of biological systems introduces variability and by-products, as well as a challenge unique to AAV production: the assembly of full capsids with correctly packaged DNA, partially filled capsids containing partial vector and/or host cell DNA, and empty capsids. Bio-Rad, Bulletin 3725 [cited 2024 Oct 28].

Therapies 52

Therapies Virus DNA Compliance 52

Agency IQ

MARCH 7, 2024

FDA updates list of chemicals in the food supply under agency review The FDA has announced an update to its List of Select Chemicals in the Food Supply Under FDA Review, which details the agency’s ongoing post-market assessments for chemicals in human food. This marks the first update to the list, which first debuted in July 2023.

FDA 40

FDA Regulations Marketing Packaging 40